Literature DB >> 29733869

Reoperation Rates and Mortality After Transurethral and Open Prostatectomy in a Long-term Nationwide Analysis: Have We Improved Over a Decade?

Klaus Eredics1, David Wachabauer2, Florian Röthlin2, Stephan Madersbacher3, Ingrid Schauer1.   

Abstract

OBJECTIVE: To assess long-term reoperation rates and mortality after transurethral resection of the prostate (TURP) and open prostatectomy (PE) as therapy for lower urinary tract symptoms due to benign prostatic enlargement.
METHODS: The present study analyzes a nationwide database of all patients who underwent TURP/open PE during 2002-2006 and who were followed up for 8 years. Actuarial cumulative incidences of reoperation (TURP, urethrotomy, bladder neck incision) and death were calculated. Data were provided by the Austrian Public Health Institute. This series was compared with a previously published almost equally sized nationwide cohort that underwent surgery during 1992-1996 in Austria.
RESULTS: Between 2002 and 2006, a total of 21,674 patients underwent TURP (n = 20,388) or open PE (n = 1,286). At 8 years, the re-TURP rate after primary TURP was 8.3% vs 4.3% after open PE. The re-TURP rate was higher in the 80+ cohort. The overall endourological reintervention rate at 8 years was 12.7% for TURP and 8.8% for open PE. Reintervention rates did not improve compared with the 1992-1996 series. The 30-day in-hospital mortality rate was 0.1% for TURP and 0.2% for open PE. Mortality rates improved by approximately 20% compared with the 1992-1996 series.
CONCLUSION: In Austria, TURP rates remained stable between 1992 and 2006, paralleled by a 50% decline of open PE. Within a decade, mortality rates declined by 20%, yet reintervention rates remained unchanged.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29733869     DOI: 10.1016/j.urology.2018.04.032

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

Review 1.  [Surgical treatment of benign prostatic hyperplasia-resection, vaporization or enucleation?]

Authors:  M Rieken; T R W Herrmann; C Füllhase
Journal:  Urologe A       Date:  2019-03       Impact factor: 0.639

Review 2.  Pharmacological and interventional treatment of benign prostatic obstruction: An evidence-based comparative review.

Authors:  Sachin Malde; Wayne Lam; Zainal Adwin; Hashim Hashim
Journal:  BJUI Compass       Date:  2021-02-03

3.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Authors:  David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm
Journal:  Blood Adv       Date:  2019-12-10

4.  Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study.

Authors:  Alisa Salmivalli; Otto Ettala; Peter J Boström; Ville Kytö
Journal:  World J Urol       Date:  2022-04-16       Impact factor: 3.661

5.  Functional capacity as a predictor of postoperative delirium in transurethral resection of prostate patients in Northeast Brazil.

Authors:  Ianna Lacerda Sampaio Braga; João Castelo-Filho; Rafael de Sousa Bezerra Pinheiro; Rodrigo Barbosa de Azevedo; Antônio Talys Ponte; Romulo Augusto da Silveira; Pedro Braga-Neto; Adriana Rolim Campos
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-22       Impact factor: 2.570

6.  In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial.

Authors:  Gautier Müllhaupt; Lukas Hechelhammer; Daniel S Engeler; Sabine Güsewell; Patrick Betschart; Valentin Zumstein; Thomas M Kessler; Hans-Peter Schmid; Livio Mordasini; Dominik Abt
Journal:  BJU Int       Date:  2019-01-28       Impact factor: 5.588

Review 7.  Is Early Surgical Treatment for Benign Prostatic Hyperplasia Preferable to Prolonged Medical Therapy: Pros and Cons.

Authors:  Cora Fogaing; Ali Alsulihem; Lysanne Campeau; Jacques Corcos
Journal:  Medicina (Kaunas)       Date:  2021-04-09       Impact factor: 2.430

8.  Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center.

Authors:  Pasquale Annese; Nicola d'Altilia; Vito Mancini; Ugo G Falagario; Francesco Del Giudice; Matteo Ferro; Ottavio de Cobelli; Angelo Porreca; Gian Maria Busetto; Giuseppe Carrieri
Journal:  Ther Adv Urol       Date:  2021-07-31

9.  Prostatic Artery Embolization for Benign Prostatic Hyperplasia: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-06-04

10.  1-year cost-utility analysis of prostate artery embolization (PAE) versus transurethral resection of the prostate (TURP) in benign prostatic hyperplasia (BPH).

Authors:  Nikisha Patel; Nathan Yung; Ganesh Vigneswaran; Laure de Preux; Drew Maclean; Mark Harris; Bhaskar Somani; Timothy Bryant; Nigel Hacking; Sachin Modi
Journal:  BMJ Surg Interv Health Technol       Date:  2021-11-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.